1. Which receptor-binding ratio most precisely defines the pharmacological property that distinguishes second-generation (atypical) antipsychotics from first-generation (typical) agents?
A) A higher ratio of dopamine D1 to dopamine D2 blockade
B) A higher ratio of muscarinic M1 to dopamine D2 blockade
C) A higher ratio of serotonin 5-HT2A to dopamine D2 receptor blockade
D) A higher ratio of histamine H1 to dopamine D2 blockade
E) A higher ratio of alpha-1 adrenergic to dopamine D2 blockade
ANSWER: C
Rationale:
The defining pharmacological criterion that discriminates atypical from typical antipsychotics is a higher ratio of serotonin 5-HT2A to dopamine D2 receptor blockade. This ratio, formalized by Meltzer and colleagues in the early 1990s, predicts a lower propensity for extrapyramidal side effects at clinically effective antipsychotic doses by disinhibiting dopamine release in the nigrostriatal pathway through 5-HT2A blockade, which partially offsets the motor consequences of D2 blockade.
Option A: Option A is incorrect because the D1:D2 ratio is not the defining discriminating criterion for atypicality; dopamine D1 receptor activity does not account for the characteristic EPS-sparing profile.
Option B: Option B is incorrect because muscarinic M1 blockade, while contributing to EPS reduction in some agents, is not the ratio that formally defines atypicality across the class.
Option D: Option D is incorrect because the H1:D2 ratio determines sedation and metabolic burden, not the atypical classification criterion.
Option E: Option E is incorrect because the alpha-1:D2 ratio governs orthostatic hypotension, not the pharmacological definition of atypicality.
2. Two distinct mechanistic models have been proposed to explain why certain second-generation antipsychotics produce very low extrapyramidal side effects despite achieving antipsychotic efficacy. Which statement most precisely describes the "fast-off" model proposed by Seeman, and how it differs from the serotonin-to-dopamine ratio model?
A) The fast-off model holds that agents such as quetiapine and clozapine dissociate rapidly from the D2 receptor, allowing endogenous dopamine to compete between doses and preventing sustained striatal blockade — in contrast to the ratio model, which attributes low EPS to disinhibition of dopamine release via 5-HT2A blockade
B) The fast-off model holds that these agents bind D2 irreversibly at low concentrations, permanently reducing receptor sensitivity, in contrast to the ratio model which proposes competitive antagonism
C) The fast-off model and the serotonin-to-dopamine ratio model are identical explanations expressed in different terminology
D) The fast-off model proposes that antipsychotic molecules exit the bloodstream rapidly, reducing CNS exposure between doses, in contrast to the ratio model which is based on receptor affinity
E) The fast-off model applies only to first-generation antipsychotics and predates the discovery of the serotonin-to-dopamine ratio
ANSWER: A
Rationale:
The fast-off model, developed by Seeman, proposes that agents such as quetiapine and clozapine achieve high momentary D2 occupancy at peak plasma concentrations but dissociate from the receptor rapidly, allowing endogenous dopamine to compete and preventing the sustained striatal D2 blockade that produces extrapyramidal side effects. This mechanistic framework is complementary to, but distinct from, the 5-HT2A:D2 ratio model: the ratio model explains low EPS through disinhibition of dopamine release via 5-HT2A blockade on nigrostriatal neurons, whereas the fast-off model explains it through the kinetics of D2 binding itself.
Option B: Option B inverts the mechanism: the defining property of the fast-off model is rapid dissociation (reversible, transient binding), not irreversible binding at low concentration.
Option C: Option C is incorrect because the two models invoke fundamentally different mechanisms — receptor dissociation kinetics versus serotonergic disinhibition of dopamine release — and are not equivalent.
Option D: Option D incorrectly locates the "fast-off" event in the bloodstream rather than at the receptor; the model specifically describes rapid D2 receptor dissociation, not rapid systemic elimination.
Option E: Option E is incorrect because the fast-off model was developed to explain atypicality in second-generation agents, particularly quetiapine and clozapine, and does not apply to first-generation antipsychotics.
3. The pronounced weight gain and metabolic dysregulation associated with clozapine and olanzapine are mediated by two receptor mechanisms acting in concert. Which pairing most precisely identifies both mechanisms and their respective contributions?
A) Dopamine D2 blockade causing increased appetite, combined with alpha-1 blockade impairing fat metabolism
B) Muscarinic M1 blockade reducing physical activity, combined with dopamine D4 blockade stimulating appetite centers
C) Alpha-2 adrenergic blockade increasing insulin resistance, combined with dopamine D2 blockade reducing energy expenditure
E) Histamine H1 blockade increasing appetite and reducing metabolic rate, combined with serotonin 5-HT2C blockade impairing hypothalamic satiety signaling
ANSWER: E
Rationale:
The metabolic weight-gain burden of clozapine and olanzapine is driven by two converging receptor mechanisms: histamine H1 blockade, which stimulates appetite and reduces metabolic rate, and serotonin 5-HT2C blockade, which impairs the hypothalamic satiety signaling that normally limits food intake. These two agents have the highest H1 and 5-HT2C affinity in the second-generation class, which is why they produce the greatest weight gain and metabolic dysregulation.
Option A: Option A is incorrect because D2 blockade does not drive weight gain through appetite stimulation, and alpha-1 blockade produces orthostatic hypotension rather than impaired fat metabolism.
Option B: Option B is incorrect because M1 blockade and D4 blockade are not the mechanisms responsible for the metabolic weight-gain syndrome; reduced physical activity from anticholinergic sedation is not the primary driver.
Option C: Option C is incorrect because alpha-2 blockade and D2 blockade are not the receptor pair mediating the metabolic syndrome; insulin resistance is a downstream consequence rather than a direct receptor-mediated mechanism for weight gain.
Option D: Option D is incorrect because D3 blockade and 5-HT1A agonism are not the pharmacological mechanisms responsible for antipsychotic-induced weight gain.
4. Clozapine carries two serious adverse effects that must be precisely distinguished from each other: agranulocytosis and seizures. Which statement most accurately differentiates their pharmacological character?
A) Both agranulocytosis and seizures are dose-dependent effects of clozapine
B) Agranulocytosis is idiosyncratic and not dose-dependent, whereas seizure risk is dose-dependent, approaching 5% at doses above 600 mg per day
C) Agranulocytosis is dose-dependent and predictable, whereas seizures are entirely idiosyncratic and unrelated to plasma levels
D) Both effects are idiosyncratic and cannot be predicted by dose or plasma level monitoring
E) Agranulocytosis occurs only in the first week of treatment, whereas seizures occur only after years of use
ANSWER: B
Rationale:
Agranulocytosis and seizures represent two distinct toxicological mechanisms. Agranulocytosis is idiosyncratic — it is not dose-dependent, is not predicted by plasma levels, and arises from an immune-mediated or toxic metabolite mechanism that does not track with the amount of drug administered. Seizures, by contrast, are dose-dependent: risk is low at standard doses and approaches 5% at doses above 600 mg per day, which is why prophylactic antiepileptic coverage is considered at high doses. Correctly discriminating these two mechanisms is essential for clinical management.
Option A: Option A is incorrect because agranulocytosis is idiosyncratic, not dose-dependent; calling both effects dose-dependent mischaracterizes the hematologic toxicity.
Option C: Option C inverts the correct relationship: it is agranulocytosis that is idiosyncratic and seizures that are dose-dependent, not the reverse.
Option D: Option D is incorrect because seizures clearly follow a dose-dependent pattern and are not idiosyncratic.
Option E: Option E is incorrect because agranulocytosis risk peaks in the first 3 to 6 months (not the first week) and carries a long tail of risk; it is not confined to any fixed time window, nor are seizures confined to late treatment.
5. The Clozapine REMS program defines specific absolute neutrophil count (ANC) thresholds that trigger escalating responses — from increased monitoring through dose interruption to permanent discontinuation. Which ANC value defines agranulocytosis, the most severe category requiring immediate action?
A) ANC below 2000 cells per microliter
B) ANC below 1500 cells per microliter
C) ANC below 1000 cells per microliter
D) ANC below 500 cells per microliter
E) ANC below 200 cells per microliter
ANSWER: D
Rationale:
Agranulocytosis is defined by the Clozapine REMS program as an ANC below 500 cells per microliter. This threshold marks the severe end of the neutropenia spectrum and requires immediate response. For context, the REMS defines mild neutropenia as ANC 1000 to 1499 cells per microliter (increased monitoring, consider interruption) and moderate to severe neutropenia as ANC below 1000 cells per microliter (interruption or discontinuation depending on degree). The 500-cell threshold is the specific value that defines agranulocytosis and must be known precisely.
Option A: Option A is incorrect because 2000 cells per microliter is within the normal-low range and does not trigger the agranulocytosis protocol.
Option B: Option B is incorrect because 1500 cells per microliter represents the lower boundary of normal for some ethnic groups and is the threshold below which the mild neutropenia protocol may begin, not agranulocytosis.
Option C: Option C is incorrect because 1000 cells per microliter is the threshold for moderate-to-severe neutropenia requiring interruption or discontinuation, but agranulocytosis is specifically defined at the lower threshold of 500.
Option E: Option E is incorrect because 200 cells per microliter, while severely low, is not the defined threshold for agranulocytosis in the REMS classification; the cutoff is 500.
6. Among all antipsychotics, which agent carries the highest dose-dependent risk of seizures, and at what approximate dose threshold does the risk become clinically significant enough to prompt consideration of prophylactic anticonvulsant coverage?
A) Clozapine, with seizure risk approaching 5% at doses above 600 mg per day
B) Haloperidol, with seizure risk approaching 5% at doses above 20 mg per day
C) Risperidone, with seizure risk approaching 5% at doses above 8 mg per day
D) Olanzapine, with seizure risk approaching 5% at doses above 30 mg per day
E) Quetiapine, with seizure risk approaching 5% at doses above 800 mg per day
ANSWER: A
Rationale:
Clozapine carries the highest seizure risk of any antipsychotic, with dose-dependent risk approaching 5% at doses above 600 mg per day. This is sufficiently high that prophylactic antiepileptic coverage is often added when doses must exceed this threshold. The mechanism involves clozapine's reduction of the seizure threshold through GABAergic and other neuronal effects that scale with plasma concentration.
Option B: Option B is incorrect because haloperidol does not carry a dose-dependent seizure risk approaching 5% at high doses; seizure risk is not a defining characteristic of haloperidol toxicity in the way it is for clozapine.
Option C: Option C is incorrect because risperidone's primary high-dose toxicity is extrapyramidal rather than epileptogenic; dose-dependent seizure risk approaching 5% is not part of its established profile.
Option D: Option D is incorrect because olanzapine, while metabolically burdensome, does not carry a recognized dose-dependent seizure risk approaching 5% at high doses.
Option E: Option E is incorrect because quetiapine's high-dose toxicity is primarily sedation, orthostatic hypotension, and metabolic effects, not dose-dependent seizures approaching 5%.
7. Clozapine produces excessive salivation (sialorrhea) despite having muscarinic M1 anticholinergic activity that would be expected to reduce salivary secretion. Which mechanism best explains this paradoxical adverse effect?
A) Clozapine stimulates alpha-1 adrenergic receptors in the salivary glands, overriding M1 inhibition
B) Clozapine's M1 anticholinergic effect is overwhelmed by its potent H1 blockade, which independently stimulates salivation
C) Clozapine acts as an agonist at muscarinic M4 receptors in the submandibular glands, stimulating secretion despite blocking M1
D) Clozapine elevates prolactin, which directly stimulates salivary gland secretion independent of autonomic tone
The paradox of clozapine-induced sialorrhea in the face of M1 anticholinergic activity is explained by clozapine's agonist activity at muscarinic M4 receptors in the submandibular glands. M4 agonism stimulates salivary secretion and overrides the drying effect of M1 blockade, producing the clinically unexpected result of excessive salivation. This precise receptor-subtype discrimination is essential for understanding why a drug with apparent anticholinergic activity can cause a cholinergic-type side effect.
Option A: Option A is incorrect because alpha-1 adrenergic stimulation is not the mechanism responsible for clozapine-induced sialorrhea; clozapine blocks, not stimulates, alpha-1 receptors.
Option B: Option B is incorrect because H1 blockade produces sedation and appetite stimulation, not salivary gland secretion; it does not account for the sialorrhea.
Option D: Option D is incorrect because prolactin elevation, while present with some antipsychotics, does not directly stimulate salivary secretion; this is not the mechanism for clozapine-associated sialorrhea.
Option E: Option E is incorrect because D2 receptor inhibition in salivary glands is not an established mechanism for sialorrhea; the effect is muscarinic, not dopaminergic.
8. A landmark effectiveness trial comparing second-generation antipsychotics in chronic schizophrenia found that one agent had the longest time to all-cause discontinuation — suggesting meaningful clinical benefit — but simultaneously produced the greatest weight gain, highest fasting glucose elevation, and most dyslipidemia of any agent in the trial. Which agent showed this combination of efficacy advantage and highest metabolic cost?
A) Risperidone
B) Olanzapine
C) Quetiapine
D) Ziprasidone
E) Clozapine
ANSWER: B
Rationale:
In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, olanzapine demonstrated the longest time to all-cause discontinuation of any agent studied, consistent with meaningful antipsychotic benefit. However, this advantage was offset by the highest metabolic burden in the trial: the greatest mean weight gain (approximately 0.9 kg per month), the most pronounced fasting glucose elevation, and the greatest dyslipidemia. This finding substantially qualified the narrative of SGAs as categorically superior to first-generation agents and established that agent selection must balance efficacy against metabolic risk.
Option A: Option A is incorrect because risperidone showed intermediate time to discontinuation and intermediate metabolic burden in CATIE, not the combination of highest efficacy and highest metabolic cost that defines olanzapine's profile.
Option C: Option C is incorrect because quetiapine did not have the longest discontinuation time or the highest metabolic burden in CATIE.
Option D: Option D is incorrect because ziprasidone is among the metabolically most favorable second-generation agents and did not produce the weight gain and dysmetabolism described.
Option E: Option E is incorrect because clozapine was not studied in CATIE (it requires REMS monitoring and was not part of the standard randomized arm); the CATIE findings describe the standard SGA comparisons.
9. Intramuscular olanzapine is used for acute agitation management. A prescribing constraint derived from post-marketing safety reports restricts its co-administration with a specific class of agents. Which co-administration is specifically contraindicated because of reported cases of severe respiratory depression and death?
A) Intramuscular olanzapine with oral haloperidol given simultaneously
B) Intramuscular olanzapine with subcutaneous insulin given in the same session
C) Intramuscular olanzapine with inhaled bronchodilators administered within the same hour
D) Intramuscular olanzapine with a parenteral benzodiazepine (intramuscular or intravenous) given in the same session
E) Intramuscular olanzapine with oral metformin given on the same day
ANSWER: D
Rationale:
The specific contraindication for intramuscular olanzapine is co-administration with a parenteral benzodiazepine — either intramuscular or intravenous — in the same clinical session. Post-marketing case reports documented severe respiratory depression and deaths when this combination was used for rapid tranquilization. The constraint applies to the parenteral route of the benzodiazepine; oral benzodiazepines are not subject to the same label restriction, though additive CNS depression remains a general concern. This is a precision-recall question because the restriction is route-specific and agent-class-specific.
Option A: Option A is incorrect because the specific contraindication involves parenteral benzodiazepines, not simultaneous oral haloperidol; combining two antipsychotics requires clinical judgment but is not the labeled safety constraint described.
Option B: Option B is incorrect because subcutaneous insulin has no pharmacodynamic interaction with intramuscular olanzapine that produces respiratory depression.
Option C: Option C is incorrect because inhaled bronchodilators do not interact with intramuscular olanzapine to produce the respiratory-depression risk described.
Option E: Option E is incorrect because oral metformin, used to manage antipsychotic-induced metabolic effects, has no acute interaction with intramuscular olanzapine.
10. Quetiapine's clinical effects change substantially depending on dose because different receptors dominate at different plasma concentrations. Which statement most precisely describes this dose-dependent receptor recruitment pattern?
A) At low doses (25 to 100 mg), H1 and alpha-1 blockade dominate, producing sedation and orthostatic hypotension with minimal antipsychotic effect; antipsychotic D2 occupancy in the therapeutic range requires doses of 400 to 800 mg per day, at which transient peak D2 occupancy is achieved despite rapid receptor dissociation
B) At low doses, D2 blockade dominates and produces the antipsychotic effect; at high doses, H1 and alpha-1 blockade emerge and cause sedation
C) Quetiapine's receptor binding profile is dose-independent; all receptor effects appear simultaneously at any dose
D) At low doses, 5-HT2A blockade produces antidepressant effects; at high doses, D2 blockade causes extrapyramidal side effects to emerge
E) At all doses, quetiapine's primary effect is 5-HT2A blockade, with H1 and D2 effects appearing only at supratherapeutic doses
ANSWER: A
Rationale:
Quetiapine's dose-dependent profile is distinctive. Its H1 affinity is very high and its alpha-1 affinity is moderate-to-high, so at low doses (25 to 100 mg) these receptor effects dominate: sedation from H1 blockade and orthostatic hypotension from alpha-1 blockade are present while D2 occupancy remains below the antipsychotic threshold. Achieving meaningful antipsychotic D2 occupancy requires doses of 400 to 800 mg per day, at which peak plasma concentrations generate transient D2 occupancy in the therapeutic range (approximately 58 to 64%), which then falls rapidly due to quetiapine's fast-off kinetics. This profile explains why low-dose quetiapine is used off-label for sedation but not for antipsychotic effect.
Option B: Option B inverts the relationship: D2 blockade is not the dominant effect at low doses — H1 and alpha-1 effects are — and the antipsychotic effect from D2 occupancy requires higher doses.
Option C: Option C is incorrect because quetiapine's receptor recruitment is explicitly dose-dependent; the clinical profile at 25 mg is fundamentally different from the profile at 600 mg.
Option D: Option D is incorrect because the dose-dependent progression is from H1/alpha-1 dominance at low doses to D2 occupancy at higher doses; 5-HT2A blockade is not the primary low-dose effect driving antidepressant activity.
Option E: Option E is incorrect because 5-HT2A blockade is present at various doses but is not the agent's primary dose-defining receptor effect; the key clinical distinction is H1 versus D2 dominance by dose range.
11. Matching each second-generation antipsychotic to its primary metabolic enzyme is essential for predicting drug interactions. Which statement correctly pairs quetiapine, clozapine, olanzapine, and risperidone with their primary hepatic metabolic routes?
A) Quetiapine is primarily CYP2D6-metabolized; clozapine is primarily CYP3A4-metabolized; olanzapine is primarily CYP2D6-metabolized; risperidone is primarily CYP1A2-metabolized
B) Quetiapine is primarily CYP1A2-metabolized; clozapine is primarily CYP2D6-metabolized; olanzapine is primarily CYP3A4-metabolized; risperidone is primarily CYP1A2-metabolized
C) All four agents are metabolized primarily by CYP3A4 with no clinically meaningful differences between them
D) Quetiapine is primarily CYP2D6-metabolized; clozapine is primarily CYP1A2-metabolized; olanzapine is primarily CYP1A2-metabolized; risperidone is primarily CYP3A4-metabolized
E) Quetiapine is primarily CYP3A4-metabolized; clozapine is primarily CYP1A2-metabolized; olanzapine is primarily CYP1A2-metabolized; risperidone is primarily CYP2D6-metabolized (to paliperidone)
ANSWER: E
Rationale:
The correct enzyme-agent pairings are: quetiapine → CYP3A4 (making it sensitive to CYP3A4 inhibitors such as azole antifungals and inducers such as carbamazepine); clozapine → CYP1A2 primarily (making it sensitive to fluvoxamine inhibition and smoking-related induction); olanzapine → CYP1A2 primarily (same smoking pharmacokinetic interaction); risperidone → CYP2D6 (converting parent drug to the active metabolite paliperidone). These distinctions are clinically consequential because each enzyme has a different inhibitor and inducer profile, and a co-medication change must be matched to the correct enzyme.
Option A: Option A is incorrect because it misassigns quetiapine to CYP2D6, clozapine to CYP3A4, and risperidone to CYP1A2 — all three are wrong.
Option B: Option B is incorrect because it misassigns quetiapine to CYP1A2 (shared with clozapine and olanzapine, not quetiapine), clozapine to CYP2D6, and olanzapine to CYP3A4.
Option C: Option C is incorrect because the four agents use distinctly different primary metabolic enzymes; treating them as interchangeable would lead to clinically harmful prescribing errors.
Option D: Option D is incorrect because it misassigns quetiapine to CYP2D6 and risperidone to CYP3A4, inverting two of the most clinically important pairings.
12. Among the second-generation antipsychotics, prolactin elevation varies markedly by agent. Which agent is most reliably associated with sustained hyperprolactinemia comparable to that produced by high-potency first-generation antipsychotics, and what receptor mechanism accounts for this?
A) Quetiapine, because its high H1 affinity stimulates prolactin release from the anterior pituitary
B) Risperidone, because its selective dopamine D2 and serotonin blockade without meaningful anticholinergic buffering produces sustained blockade of the tuberoinfundibular dopamine pathway, removing the inhibitory tone on prolactin secretion
C) Clozapine, because its broad multi-receptor blockade including D4 produces paradoxical prolactin elevation
D) Olanzapine, because its 5-HT2C blockade directly stimulates prolactin-releasing hormone
E) Aripiprazole, because its D2 partial agonism raises prolactin above baseline
ANSWER: B
Rationale:
Risperidone is the second-generation antipsychotic most consistently associated with sustained, dose-dependent hyperprolactinemia comparable to high-potency first-generation agents. The mechanism is selective dopamine D2 and serotonin receptor blockade without the anticholinergic, histaminic, or other receptor activity that attenuates tuberoinfundibular D2 blockade in other agents. Blocking D2 receptors in the tuberoinfundibular pathway removes dopamine's tonic inhibition of prolactin secretion, producing sustained prolactin elevation, amenorrhea, galactorrhea, sexual dysfunction, and — with long-term exposure — reduced bone density.
Option A: Option A is incorrect because quetiapine is prolactin-sparing; its fast-off D2 kinetics and receptor profile do not produce sustained tuberoinfundibular blockade, and H1 blockade does not stimulate prolactin.
Option C: Option C is incorrect because clozapine is prolactin-sparing; its low sustained D2 occupancy and multi-receptor profile preserve sufficient tuberoinfundibular dopamine tone.
Option D: Option D is incorrect because olanzapine produces, at most, modest and transient prolactin elevation; 5-HT2C blockade does not directly stimulate prolactin-releasing hormone in the manner described.
Option E: Option E is incorrect because aripiprazole, as a D2 partial agonist, tends to normalize or reduce elevated prolactin rather than raising it above baseline.
13. Paliperidone (9-hydroxyrisperidone) has a pharmacokinetic profile that distinguishes it from virtually all other antipsychotics. Which set of properties most precisely characterizes paliperidone's elimination and its clinical implications?
A) Paliperidone is primarily CYP2D6-metabolized and requires dose reduction in hepatic impairment
B) Paliperidone is primarily CYP3A4-metabolized and is sensitive to azole antifungal co-administration
C) Paliperidone undergoes minimal hepatic metabolism and is eliminated largely unchanged by renal excretion, making dose adjustment necessary in renal impairment rather than hepatic impairment, and rendering its plasma levels relatively insensitive to CYP enzyme inducers and inhibitors
D) Paliperidone is eliminated by biliary excretion and requires dose reduction in both hepatic and renal impairment equally
E) Paliperidone is a prodrug that requires hepatic activation before producing any pharmacological effect
ANSWER: C
Rationale:
Paliperidone is unique among antipsychotics in being eliminated primarily unchanged by the kidneys — approximately 59% of a dose is excreted unchanged in urine — with minimal hepatic metabolism. This means its plasma levels are largely unaffected by CYP enzyme inducers and inhibitors, and that dose adjustment is driven by renal function rather than hepatic function, the reverse of most antipsychotics. The primary clinical advantage is pharmacokinetic predictability: the drug interaction burden from CYP-active comedications is substantially reduced compared with risperidone.
Option A: Option A is incorrect because paliperidone, unlike its parent drug risperidone, bypasses CYP2D6 rather than depending on it; hepatic metabolism is minimal.
Option B: Option B is incorrect because CYP3A4 is the primary route for quetiapine, not paliperidone; paliperidone's minimal hepatic processing makes it insensitive to CYP3A4 inhibitors.
Option D: Option D is incorrect because biliary excretion is not the primary elimination route; renal excretion of unchanged drug is the defining characteristic.
Option E: Option E is incorrect because paliperidone is the active metabolite of risperidone, not a prodrug; it is pharmacologically active as administered, without requiring further hepatic bioactivation.
14. Risperidone behaves as an atypical antipsychotic at low doses but loses this profile above a specific dose threshold. Which statement most precisely characterizes risperidone's dose-dependent extrapyramidal side-effect (EPS) profile and the receptor mechanism underlying the threshold?
A) Risperidone produces EPS independent of dose because it lacks any 5-HT2A activity
B) Risperidone produces EPS only at doses below 4 mg per day, where D2 occupancy is insufficient for antipsychotic effect
C) Risperidone's EPS risk is constant across all doses because its 5-HT2A:D2 ratio does not change with dose
D) Above approximately 6 to 8 mg per day, striatal D2 occupancy crosses the EPS threshold; unlike olanzapine or quetiapine, risperidone lacks the H1 or anticholinergic buffering that attenuates EPS emergence in those agents, making dose-dependent EPS clinically prominent
E) Risperidone produces EPS only via the depot (long-acting injectable) formulation, not via oral dosing
ANSWER: D
Rationale:
Risperidone is atypical at doses below approximately 6 to 8 mg per day, where its 5-HT2A:D2 ratio keeps nigrostriatal D2 occupancy below the EPS threshold. Above this range, D2 occupancy crosses the threshold and risperidone begins producing parkinsonism and akathisia at rates approaching those of high-potency first-generation agents. Critically, risperidone lacks the H1 or anticholinergic receptor activity present in olanzapine and quetiapine that partially attenuates EPS emergence in those agents. This makes dose optimization especially consequential for risperidone: doses above 6 mg per day offer diminishing antipsychotic returns with increasing EPS cost.
Option A: Option A is incorrect because risperidone does have 5-HT2A activity and its EPS profile is clearly dose-dependent rather than constant.
Option B: Option B inverts the direction: EPS emerges as doses increase above the threshold, not at doses below it; low doses are the EPS-sparing range.
Option C: Option C is incorrect because, while the intrinsic 5-HT2A:D2 ratio of the molecule does not change with dose, the absolute level of D2 occupancy does increase with dose and crosses the EPS threshold at higher doses.
Option E: Option E is incorrect because dose-dependent EPS is a pharmacological property of risperidone at any route or formulation; it is not restricted to the long-acting injectable form.
15. Fluvoxamine, a selective serotonin reuptake inhibitor used for obsessive-compulsive disorder, is a potent inhibitor of CYP1A2 — the primary enzyme responsible for clozapine clearance. Which statement most precisely describes the magnitude, direction, and clinical exploitation of this interaction?
A) Fluvoxamine raises clozapine plasma levels 5- to 10-fold at typical doses of 50 to 100 mg per day; this interaction has been deliberately used to allow lower clozapine doses while maintaining therapeutic levels, thereby reducing agranulocytosis risk and improving tolerability — but requires careful plasma-level monitoring
B) Fluvoxamine lowers clozapine plasma levels by 5- to 10-fold by inducing CYP1A2, potentially causing loss of antipsychotic effect
C) Fluvoxamine has no clinically meaningful effect on clozapine levels because clozapine is primarily renally eliminated
D) Fluvoxamine raises clozapine levels modestly (approximately 20 to 30%) through a non-CYP mechanism, which is clinically insignificant
E) Fluvoxamine lowers clozapine levels through competitive displacement from plasma protein binding sites, requiring upward dose adjustment
ANSWER: A
Rationale:
Fluvoxamine is a potent CYP1A2 inhibitor, and clozapine is cleared approximately 70 to 80% by CYP1A2. Inhibiting this enzyme with fluvoxamine at doses of 50 to 100 mg per day raises clozapine plasma levels 5- to 10-fold — a pharmacokinetically massive interaction. In clinical practice, this has been deliberately exploited: adding low-dose fluvoxamine allows the clozapine dose to be substantially reduced while maintaining therapeutic plasma concentrations, potentially reducing the dose-independent agranulocytosis risk and improving tolerability. This strategy requires careful therapeutic drug monitoring to avoid toxicity from the elevated clozapine levels.
Option B: Option B inverts the pharmacology: fluvoxamine inhibits, not induces, CYP1A2; inhibition raises levels rather than lowering them.
Option C: Option C is incorrect because clozapine is primarily hepatically (not renally) cleared, predominantly by CYP1A2, making this one of the most clinically significant drug interactions in psychopharmacology.
Option D: Option D incorrectly characterizes both the magnitude (it is 5- to 10-fold, not 20 to 30%) and the mechanism (it is CYP1A2 inhibition, not a non-CYP interaction).
Option E: Option E is incorrect because fluvoxamine's interaction operates through CYP1A2 enzyme inhibition reducing metabolism, not through protein-binding displacement, and the direction of change is an increase in levels requiring possible dose reduction, not an upward adjustment.
16. Carbamazepine is a broad enzyme inducer affecting CYP1A2, CYP3A4, and CYP2D6, and independently carries a risk of bone marrow suppression. Precisely distinguishing its interaction with clozapine from the fluvoxamine-clozapine interaction is essential for safe prescribing. Which statement most accurately characterizes the carbamazepine-clozapine interaction and the reason it is generally contraindicated?
A) Carbamazepine inhibits CYP1A2, raising clozapine levels substantially, with the risk of toxicity driving the contraindication
B) Carbamazepine and clozapine are contraindicated because they both prolong the QTc interval, with an additive risk of torsades de pointes
C) Carbamazepine displaces clozapine from plasma protein binding, raising free clozapine levels and causing toxicity
D) Carbamazepine inhibits CYP3A4 and thereby blocks clozapine's primary metabolic route, raising levels to dangerous concentrations
E) Carbamazepine induces CYP1A2 (and other CYPs), substantially lowering clozapine plasma levels and threatening loss of efficacy, while simultaneously adding an independent bone marrow suppression risk that compounds clozapine's own agranulocytosis risk — the dual hazard of subtherapeutic levels plus additive marrow toxicity is the basis for the general contraindication
ANSWER: E
Rationale:
The carbamazepine-clozapine contraindication rests on two distinct and compounding mechanisms. First, carbamazepine is a broad CYP inducer (including CYP1A2, the primary clozapine clearance enzyme) that substantially lowers clozapine plasma levels, potentially producing subtherapeutic concentrations and loss of antipsychotic efficacy. Second, carbamazepine independently carries a risk of bone marrow suppression, which directly compounds clozapine's own idiosyncratic agranulocytosis risk. This dual hazard — underexposure to the antipsychotic plus additive marrow toxicity — makes the combination generally contraindicated. This precisely discriminates from the fluvoxamine interaction, which is an inhibitor that raises levels rather than an inducer that lowers them.
Option A: Option A inverts the pharmacology: carbamazepine is an enzyme inducer, not an inhibitor; it lowers clozapine levels rather than raising them, which is the opposite of fluvoxamine's effect.
Option B: Option B is incorrect because QTc prolongation is not the primary basis for the carbamazepine-clozapine contraindication; the concern is enzyme induction reducing efficacy and additive marrow suppression.
Option C: Option C is incorrect because protein-binding displacement is not the mechanism; the interaction operates through CYP enzyme induction reducing hepatic clearance — or in this case, accelerating it.
Option D: Option D is incorrect because carbamazepine is an enzyme inducer, not an inhibitor, and the primary CYP route for clozapine is CYP1A2, not CYP3A4; induction accelerates, rather than blocks, metabolism.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.